Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBITDA: 2019-2024

Historic EBITDA for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to -$235.6 million.

  • Maravai Lifesciences Holdings' EBITDA rose 75.22% to -$41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.2 million, marking a year-over-year increase of 5.31%. This contributed to the annual value of -$235.6 million for FY2024, which is 644.49% down from last year.
  • Maravai Lifesciences Holdings' EBITDA amounted to -$235.6 million in FY2024, which was down 644.49% from -$31.6 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' EBITDA ranged from a high of $574.2 million in FY2022 and a low of -$235.6 million during FY2024.
  • Over the past 3 years, Maravai Lifesciences Holdings' median EBITDA value was -$31.6 million (recorded in 2023), while the average stood at $102.3 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' EBITDA surged by 399.84% in 2020 and then slumped by 644.49% in 2024.
  • Maravai Lifesciences Holdings' EBITDA (Yearly) stood at $119.9 million in 2020, then surged by 362.58% to $554.6 million in 2021, then rose by 3.53% to $574.2 million in 2022, then slumped by 105.51% to -$31.6 million in 2023, then plummeted by 644.49% to -$235.6 million in 2024.